Blog Archive

Friday, May 19, 2023

05-18-2023-2231 - A statute of limitations (known in civil law systems as a prescriptive period)

A statute of limitations, (known in civil law systems as a prescriptive period), is a law passed by a legislative body to set the maximum time after an event within which legal proceedings may be initiated.[1][2] In most jurisdictions, such periods exist for both criminal law and civil law such as contract law and property law, though often under different names and with varying details.

When the time which is specified in a statute of limitations runs out, a claim might no longer be filed or, if it is filed, it may be subject to dismissal if the defense against that claim is raised that the claim is time-barred as having been filed after the statutory limitations period.[3]

When a statute of limitations expires in a criminal case, the courts no longer have jurisdiction. Most common crimes that have statutes of limitations are distinguished from particularly serious crimes because the latter claims may be brought at any time.

In civil law systems, such provisions are typically part of their civil and criminal codes. The cause of action dictates the statute of limitations, which can be reduced or extended in order to ensure a full and fair trial.[4] The intention of these laws is to facilitate resolution within a "reasonable" period of time.[5] What amount of time is considered "reasonable" varies from country to country.[6] In the United States, it may vary from jurisdiction to jurisdiction and state to state. Internationally, the statute of limitations may vary from one civil or criminal action to another. Some countries have no statute of limitations whatsoever.

Analysis of a statute of limitations also requires the examination of any associated statute of repose, tolling provisions, and exclusions. 

https://en.wikipedia.org/wiki/Statute_of_limitations

Limitations and exceptions to copyright are provisions, in local copyright law or the Berne Convention, which allow for copyrighted works to be used without a license from the copyright owner.

Limitations and exceptions to copyright relate to a number of important considerations such as market failure, freedom of speech,[1] education and equality of access (such as by the visually impaired). Some view limitations and exceptions as "user rights"—seeing user rights as providing an essential balance to the rights of the copyright owners. There is no consensus among copyright experts as to whether user rights are rights or simply limitations on copyright. The concept of user rights has been recognised by courts, including the Canadian Supreme Court,[2] which classed "fair dealing" as such a user right. These kinds of disagreements in philosophy are quite common in the philosophy of copyright, where debates about jurisprudential reasoning tend to act as proxies for more substantial disagreements about good policy. 

https://en.wikipedia.org/wiki/Limitations_and_exceptions_to_copyright

https://en.wikipedia.org/wiki/Pirate_Party

https://en.wikipedia.org/wiki/Old_Norse

https://en.wikipedia.org/wiki/Freedom_of_speech#Limitations

 https://en.wikipedia.org/wiki/Censorship

https://en.wikipedia.org/wiki/Philosophy_of_copyright

 

https://en.wikipedia.org/wiki/Intellectual_property

https://en.wikipedia.org/wiki/Patent

https://en.wikipedia.org/wiki/Gang

https://en.wikipedia.org/wiki/Censorship


The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. The Act provided that the FDA was entitled to collect a substantial application fee from drug manufacturers at the time a New Drug Application (NDA) or Biologics License Application (BLA) was submitted, with those funds designated for use only in Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) drug approval activities. In order to continue collecting such fees, the FDA is required to meet certain performance benchmarks, primarily related to the speed of certain activities within the NDA review process. 

https://en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act

 

From Wikipedia, the free encyclopedia

A biologics license application (BLA) is defined by the U.S. Food and Drug Administration (FDA) as follows:

The biologics license application is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). The BLA is regulated under 21 CFR 600 – 680. A BLA is submitted by any legal person or entity who is engaged in manufacture or an applicant for a license who takes responsibility for compliance with product and establishment standards. Form 356h specifies the requirements for a BLA. This includes:

  • Applicant information
  • Product/manufacturing information
  • Pre-clinical studies
  • Clinical studies
  • Labeling[1]

Some biological products are regulated by the Center for Drug Evaluation and Research (CDER) while others are regulated by Center for Biologics Evaluation and Research (CBER).[2]

A BLA is submitted after an investigational new drug has been approved. If the Form 356h is missing information, the FDA will reply within 74 days.[3] A BLA asserts that the product is "safe, pure, and potent", the manufacturing facilities are inspectable, and each package of the product bears the license number.

After approval, annual reports, reports on adverse events, manufacturing changes, and labeling changes must be submitted.

See also

References


  • "Biologics License Applications (BLA) Process (CBER)". FDA. 2015. Retrieved July 9, 2016.

  • "Archived copy" (PDF). Food and Drug Administration. Archived from the original (PDF) on February 3, 2017. Retrieved January 27, 2017.

    1. Group, The FDA. "The Biologics License Application (BLA) Process Explained". www.thefdagroup.com.

    No comments:

    Post a Comment